Tom Brady-backed Telehealth AI Startup eMed Secures $200 Mn, Crosses $2 Bn Valuation

eMed’s digital platform offers telehealth consultations, at-home diagnostics, and ongoing clinical support, with the focus area of enabling access to GLP-1 medications.

Miami-based telehealth AI startup eMed has raised USD 200 Mn in a Series A round, pushing its valuation beyond USD 2 Bn, as the startup looks to strengthen its AI-driven care delivery model and expand access to GLP-1-based treatment programs for employers.

Founded in 2020, the startup initially gained prominence during the COVID-19 pandemic through at-home testing solutions before pivoting toward broader digital health services. It has since repositioned itself as a population health platform, focusing on chronic disease management and employer-sponsored healthcare models.

The telehealth startup has also expanded its footprint through acquisitions, including parts of Babylon’s UK telehealth operations, strengthening its presence in preventive care.

The latest funding round saw participation from AON Consulting, along with high-profile backers such as Tom Brady, who also serves as the startup’s founding Chief Wellness Officer; CEO Linda Yaccarino; and investors including Jeff Aronin, Ara Cohen, Antonio Gracias, Joe Lonsdale, R.J. Melman, and Tom Ricketts.

At the core of eMed’s offering is a digital platform that combines telehealth consultations, at-home diagnostics, and ongoing clinical support. A key focus area is enabling access to GLP-1 medications, a class of drugs increasingly used for obesity and diabetes management but often restricted due to high costs and limited insurance coverage.

The startup integrates medication access with continuous monitoring and side-effect management, positioning its model as a comprehensive care pathway rather than a standalone prescription service.

The funding will also support the development of a capitated care model aimed at helping employers better manage healthcare spending while expanding access to high-demand therapies.

“I believe eMed's empathic agentic AI platform, combined with the strength of its people and partners, represents a true winning formula. That conviction is why I've chosen to invest both my time as founding chief wellness officer and my capital in the company,” Brady said in a statement.

With this funding, eMed is positioning itself at the intersection of AI-driven healthcare delivery and employer-led health benefits, aiming to play a larger role in reshaping how chronic conditions are managed at scale.

Stay tuned for more such updates on Digital Health News